Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
نویسندگان
چکیده
منابع مشابه
A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma Jonathon B. Cohen, Kami J. Maddocks, Ying Huang, Beth A. Christian, Samantha M. Jaglowski, Christopher R. Flowers & Kristie A. Blum To cite this article: Jonathon B. Cohen, Kami J. Maddocks, Ying Huang, Beth A. Christian, Samantha M. Jaglowski, Christopher R. Flowers & Kristie A. Blum (2017): A phase...
متن کاملA Case Report of a Metastatic Primary Gastric Lymphoma; Diffuse Large B-Cell or Burkitt Lymphoma?
Introduction: Primary gastric lymphoma (PGL) is a rare tumor, whose differential diagnosis may become complicated without precise immunohistochemistry (IHC) and genetic analysis. Case Presentation: A 33-year-old woman presented with gastric cancer and had undergone gastrectomy without precise IHC and staging in another center. Inappropriate IHC after surgery showed diffuse large B-cell lymphom...
متن کاملA Case Report of a Metastatic Primary Gastric Lymphoma; Diffuse Large B-Cell or Burkitt Lymphoma?
Introduction: Primary gastric lymphoma (PGL) is a rare tumor, whose differential diagnosis may become complicated without precise immunohistochemistry (IHC) and genetic analysis. Case Presentation: A 33-year-old woman presented with gastric cancer and had undergone gastrectomy without precise IHC and staging in another center. Inappropriate IHC after surgery showed diffuse large B-cell lymphom...
متن کاملPhase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
The majority of diffuse large B-cell lymphoma (DLBCL) tumors contain mutations in histone-modifying enzymes (HMEs), indicating a potential therapeutic benefit of histone deacetylase inhibitors (HDIs), and preclinical data suggest that HDIs augment the effect of rituximab. In this randomized phase 2 study, we evaluated the response rate and toxicity of panobinostat, a pan-HDI administered 30 mg ...
متن کاملThe Evaluation of Immunophenotypes in Diffuse Large B Cell Lymphoma: A Single Center Study
Background: Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of mature B lymphocytes. It is known as a heterogeneous disease with variable therapeutic responses and alternative therapies. Morphological and immunophenotypical evaluation of the biopsy specimens can help diagnose DLBCL. Methods: In the current study, 44 patients were chosen from Shaheed Sadoghi Hospital (2010&nda...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Haematology
سال: 2020
ISSN: 2352-3026
DOI: 10.1016/s2352-3026(20)30120-4